Experimental combo for advanced lung and bladder cancer shows early safety data

NCT ID NCT02298153

Terminated Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Apr 30, 2026 · Last updated May 01, 2026 · Updated 1 time

Summary

This early-phase study tested a combination of two drugs (atezolizumab and epacadostat) in 29 adults with advanced lung or bladder cancer that had already been treated with chemotherapy. The main goal was to check safety and find the best dose. The study was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CARCINOMA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Harvard-Mass General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Pinnacle Oncology Hematology

Scottsdale, Arizona, 85258, United States
University of Washington

Seattle, Washington, 98109, United States
Yale University

New Haven, Connecticut, 06510, United States

Conditions

Explore the condition pages connected to this study.

NSCLC (NON-SMALL CELL LUNG CARCINOMA) UC (UROTHELIAL CANCER)